Literature DB >> 26879092

Parallel Atrophy of Cortex and Basal Forebrain Cholinergic System in Mild Cognitive Impairment.

Ingo Kilimann1,2, Lucrezia Hausner3, Andreas Fellgiebel4, Massimo Filippi5, Till J Würdemann1, Helmut Heinsen6, Stefan J Teipel1,2.   

Abstract

The basal forebrain cholinergic system (BFCS) is the major source of acetylcholine for the cerebral cortex in humans. The aim was to analyze the pattern of BFCS and cortical atrophy in MCI patients to find evidence for a parallel atrophy along corticotopic organization of BFCS projections. BFCS volume and cortical thickness were analyzed using high-definition 3D structural magnetic resonance imaging data from 1.5-T and 3.0-T scanners of 64 MCI individuals and 62 cognitively healthy elderly controls from the European DTI study in dementia. BFCS volume reduction was correlated with thinning of cortical areas with known BFCS projections, such as Ch2 and parahippocampal gyrus in the MCI group, but not in the control group. Additionally, we found correlations between BFCS and cortex atrophy beyond the known corticotopic projections, such as between Ch4p and the cingulate gyrus. BFCS volume reduction was associated with regional thinning of cortical areas that included, but was not restricted to, the pattern of corticotopic projections of the BFCS as derived from animal studies. Our in vivo results may indicate the existence of more extended projections from the BFCS to the cerebral cortex in humans than that known from prior studies with animals.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer's disease; European DTI study on dementia; biomarker; dementia; neurodegeneration

Mesh:

Substances:

Year:  2017        PMID: 26879092     DOI: 10.1093/cercor/bhw019

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  15 in total

Review 1.  Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.

Authors:  Donald E Moss; Ruth G Perez
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

2.  Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections.

Authors:  Taylor W Schmitz; Marieke Mur; Meghmik Aghourian; Marc-Andre Bedard; R Nathan Spreng
Journal:  Cell Rep       Date:  2018-07-03       Impact factor: 9.423

3.  New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders.

Authors:  Chesney E Craig; Nicola J Ray; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Behav Neurosci Rep       Date:  2020-10-09

4.  Meynert nucleus-related cortical thinning in Parkinson's disease with mild cognitive impairment.

Authors:  Siming Rong; Yan Li; Bing Li; Kun Nie; Piao Zhang; Tongtong Cai; Mingjin Mei; Lijuan Wang; Yuhu Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-04

5.  Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults.

Authors:  Yi-Fang Chuang; Palchamy Elango; Christopher E Gonzalez; Madhav Thambisetty
Journal:  Alzheimers Dement (N Y)       Date:  2017-07-19

6.  In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.

Authors:  Nicola J Ray; Steven Bradburn; Christopher Murgatroyd; Umar Toseeb; Pablo Mir; George K Kountouriotis; Stefan J Teipel; Michel J Grothe
Journal:  Brain       Date:  2018-01-01       Impact factor: 13.501

7.  A Complex Interplay of Vitamin B1 and B6 Metabolism with Cognition, Brain Structure, and Functional Connectivity in Older Adults.

Authors:  Kai Jannusch; Christiane Jockwitz; Hans-Jürgen Bidmon; Susanne Moebus; Katrin Amunts; Svenja Caspers
Journal:  Front Neurosci       Date:  2017-10-27       Impact factor: 4.677

8.  MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

Authors:  Ziqiang Lin; Eugene Kim; Mohi Ahmed; Gang Han; Camilla Simmons; Yushi Redhead; Jack Bartlett; Luis Emiliano Pena Altamira; Isobel Callaghan; Matthew A White; Nisha Singh; Stephen Sawiak; Tara Spires-Jones; Anthony C Vernon; Michael P Coleman; Jeremy Green; Christopher Henstridge; Jeffrey S Davies; Diana Cash; Jemeen Sreedharan
Journal:  Brain Commun       Date:  2021-05-27

9.  Interleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons.

Authors:  Raymond Wong; Nikolett Lénárt; Laura Hill; Lauren Toms; Graham Coutts; Bernadett Martinecz; Eszter Császár; Gábor Nyiri; Athina Papaemmanouil; Ari Waisman; Werner Müller; Markus Schwaninger; Nancy Rothwell; Sheila Francis; Emmanuel Pinteaux; Adam Denés; Stuart M Allan
Journal:  Brain Behav Immun       Date:  2018-11-16       Impact factor: 7.217

10.  Kai Xin San ameliorates scopolamine-induced cognitive dysfunction.

Authors:  Yu-Min Xu; Xin-Chen Wang; Ting-Ting Xu; Hong-Ying Li; Shang-Yan Hei; Na-Chuan Luo; Hong Wang; Wei Zhao; Shu-Huan Fang; Yun-Bo Chen; Li Guan; Yong-Qi Fang; Shi-Jie Zhang; Qi Wang; Wei-Xiong Liang
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.